Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > May 27, 2025
Daily News
May 27, 2025
- MOF Panel Again Presses for Expansion of CEA Scheme: “Spring” Proposal
May 27, 2025
- Taking on Solid Tumors - 1: Japan Sees Rush of Bispecific Approvals with Good Progress in Blood Cancers, and More
May 27, 2025
- Honebuto Outline Includes “Raise in Official Prices,” but Details Yet Unknown
May 27, 2025
- Lilly/NCNP Tie Up for Research on APOE Gene Testing
May 27, 2025
- Decline of Obesity Population Might Curb Rise in Healthcare Costs: Lilly
May 27, 2025
- Japan Govt Plans Consortium for Driving Domestic Production of Radioisotopes
May 27, 2025
- Mitsubishi Tanabe Taps Moderna’s Nagayama as New EVP Post
May 27, 2025
- JPMA Revises Definition of Promotion in Code of Practice
May 27, 2025
- Topic of OTC-Like Drugs Dropped from 3-Party Talks: Ishin
May 27, 2025
- Moderna Launches Prefilled Version of Spikevax in Japan
May 27, 2025
- Next Wave of ALS Drugs Emerging as Novartis, Nipro Enter Development Fray
May 27, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…